1. Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719–25. 26158353
2. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82. doi: 10.15585/mmwr.mm6450a3 26720857
3. Public Health Agency of Canada. HIV transmission risk: a summary of the evidence. Ottawa: Public Health Agency of Canada; 2013 [cited 2015 Feb 9]. http://www.catie.ca/sites/default/files/HIV-TRANSMISSION-RISK-EN.pdf.
4. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report. Atlanta: Centers for Disease Control and Prevention; 2012 [cited 2014 Aug 12]. https://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf.
5. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2013. HIV Surveillance Report. Atlanta: Centers for Disease Control and Prevention; 2013 [cited 2015 Jul 15]. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2013-vol-25.pdf.
6. Centers for Disease Control and Prevention. HIV-associated behaviors among injecting-drug users—23 cities, United States, May 2005–February 2006. MMWR Morb Mortal Wkly Rep. 2009;58(13):329–32. 19357632
7. Centers for Disease Control and Prevention. HIV infection and HIV-associated behaviors among injecting drug users—20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61(8):133–8. 22377843
8. Frieden TR, Foti KE, Mermin J. Applying public health principles to the HIV epidemic—how are we doing? N Engl J Med. 2015;373(23):2281–7. doi: 10.1056/NEJMms1513641 26624243
9. Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6):815–26. doi: 10.1097/QAD.0000000000001039 26836787
10. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi: 10.1136/bmj.e5945 23038795
11. Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O’Connor PG, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87–92. doi: 10.1016/j.jsat.2007.08.004 17933486
12. Burt RD, Thiede H. Reduction in needle sharing among Seattle-area injection drug users across 4 surveys, 1994–2013. Am J Public Health. 2016;106(2):301–7. doi: 10.2105/AJPH.2015.302959 26691117
13. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. doi: 10.1016/S0140-6736(13)61127-7 23769234
14. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40(1):96–101. 16123689
15. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Atlanta: Centers for Disease Control and Prevention; 2014 [cited 2014 Jun 12]. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf.
16. Bernard CL, Brandeau ML, Owens DK, Humphreys K, Bendavid E, Weyant C, et al. Cost-effectiveness of HIV preexposure prophylaxis for people who inject drugs in the United States. Ann Intern Med. 2016;165(1):10–9.
17. Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014;63(6):1–51. 24990587
18. Spiller MW, Broz D, Wejnert C, Nerlander L, Paz-Bailey G. HIV infection and HIV-associated behaviors among persons who inject drugs—20 cities, United States, 2012. MMWR Morb Mortal Wkly Rep. 2015;64(10):270–5. 25789742
19. Centers for Disease Control and Prevention. Prevalence and awareness of HIV infection among men who have sex with men—21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep. 2010;59(37):1201–7. 20864920
20. Centers for Disease Control and Prevention. HIV testing and risk behaviors among gay, bisexual, and other men who have sex with men—United States. MMWR Morb Mortal Wkly Rep. 2013;62(47):958–62. 24280915
21. Hall HI, Green TA, Wolitski RJ, Holtgrave DR, Rhodes P, Lehman JS, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6. doi: 10.1097/QAI.0b013e3181e8f90c 20634702
22. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6(1):9–17. 12535234
23. Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34(12 Suppl):DS197–9. 8969326
24. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, Friedman R, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81(3):377–400. doi: 10.1093/jurban/jth125 15273263
25. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI, et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992–2007. PLoS ONE. 2013;8(6):e64789. doi: 10.1371/journal.pone.0064789 23755143
26. Centers for Disease Control and Prevention. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2012;61(RR-5):1–40. 23135062
27. Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS ONE. 2012;7(9):e45176. doi: 10.1371/journal.pone.0045176 23028828
28. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90(7):1100–11. 10897189
29. Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, Martinez A, et al. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health. 2005;82(1 Suppl 1):i43–50. doi: 10.1093/jurban/jti023 15738321
30. Bellis DJ. Reduction of AIDS risk among 41 heroin addicted female street prostitutes: effects of free methadone maintenance. J Addict Dis. 1993;12(1):7–23. doi: 10.1300/J069v12n01_02 8381030
31. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect. 2006;82(Suppl 3):iii56–63.
32. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS ONE. 2014;9(1):e86584. doi: 10.1371/journal.pone.0086584 24489747
33. McCollister KE, French MT, Pyne JM, Booth B, Rapp R, Carr C. The cost of treating addiction from the client’s perspective: Results from a multi-modality application of the Client DATCAP. Drug Alcohol Depend. 2009;104(3):241–8. doi: 10.1016/j.drugalcdep.2009.05.014 19574000
34. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992;5(11):1116–8. 1403641
35. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S133–8.
36. Knittel S. Bill seeks to end the ban on syringe exchange programs. Seattle Gay News. 2009 Jul 17 [cited 2016 Jan 22]. http://www.sgn.org/sgnnews37_29/page14.cfm.
37. Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(48):1337–41. doi: 10.15585/mmwr.mm6448a3 26655918
38. Kapadia F, Latka MH, Hudson SM, Golub ET, Campbell JV, Bailey S, et al. Correlates of consistent condom use with main partners by partnership patterns among young adult male injection drug users from five US cities. Drug Alcohol Depend. 2007;91(Suppl 1):S56–63.
39. Centers for Disease Control and Prevention. HIV/AIDS: infographics and posters. Atlanta: Centers for Disease Control and Prevention; 2015 [cited 2015 Jun 29]. https://www.cdc.gov/hiv/library/infographics/.
40. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18(4):262–70. doi: 10.1016/j.drugpo.2006.12.014 17689374
41. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687–93. doi: 10.1086/590501 18662132
42. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355. doi: 10.1371/journal.pone.0081355 24367482
43. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS. 2014;28(2):257–65. doi: 10.1097/QAD.0000000000000078 24105030
44. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778–89. doi: 10.7326/0003-4819-153-12-201012210-00004 21173412
45. Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96. doi: 10.1001/jamainternmed.2014.8180 25706928
46. Centers for Disease Control and Prevention. Understanding the HIV care continuum. Atlanta: Centers for Disease Control and Prevention; 2014 [cited 2016 Mar 31]; http://www.cdc.gov/hiv/pdf/DHAP_Continuum.pdf.
47. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85. doi: 10.1056/NEJMsa042657 15703422
48. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541–50. doi: 10.7326/0003-4819-156-8-201204170-00001 22508731
49. Law Enforcement Assisted Diversion. About LEAD. Seattle: Law Enforcement Assisted Diversion; 2016 [cited 2016 Mar 15]. http://leadkingcounty.org/about/.
50. Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Sun H, et al. Effect of management strategies and clinical status on costs of care for advanced HIV. Am J Manag Care. 2014;20(5):e129–37. 25326927
51. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95. doi: 10.1056/NEJMsa042088 15703423
52. New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: questions and answers. Albany: New York State Department of Health; 2012 [cited 2015 Feb 9]. https://www.health.ny.gov/publications/0265/.
53. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15. doi: 10.1086/597095 19193111
54. US Department of Veterans Affairs. National Acquisition Center (CCST). Washington (District of Columbia): US Department of Veterans Affairs; 2015 [cited 2015 Apr 1]. https://www.va.gov/nac/.
55. Arias E. United States life tables, 2010. Natl Vital Stat Rep. 2014;63(7):1–63. 25383611
56. Sionean C, Le BC, Hageman K, Oster AM, Wejnert C, Hess KL, et al. HIV risk, prevention, and testing behaviors among heterosexuals at increased risk for HIV infection—National HIV Behavioral Surveillance System, 21 U.S. cities, 2010. MMWR Surveill Summ. 2014;63(14):1–39. 25522191
57. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect. 1999;31(6):272–9. 10614517
58. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189(10):1785–92. doi: 10.1086/386333 15122514
59. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22(6):475–81. doi: 10.1177/0272989X02238300 12458977
60. Pollack HA, D’Aunno T. HIV testing and counseling in the nation’s outpatient substance abuse treatment system, 1995–2005. J Subst Abuse Treat. 2010;38(4):307–16. doi: 10.1016/j.jsat.2009.12.004 20171038
61. Sanchez T, Finlayson T, Drake A, Behel S, Cribbin M, Dinenno E, et al. Human immunodeficiency virus (HIV) risk, prevention, and testing behaviors—United States, National HIV Behavioral Surveillance System: men who have sex with men, November 2003–April 2005. MMWR Surveill Summ. 2006;55(6):1–16. 16826162
62. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267–78. doi: 10.1080/09652140120070328 11672491
63. Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27(6):669–76. doi: 10.1007/s11606-011-1962-8 22215271
64. Kim NJ, Jin H, McFarland W, Raymond HF. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005–2012. Int J Drug Policy. 2015;26(12):1238–43. doi: 10.1016/j.drugpo.2015.08.013 26365768
65. Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS. 2012;26(17):2201–10. doi: 10.1097/QAD.0b013e3283578b5d 22914579
66. Adams J. HIV Outbreak in Indiana. N Engl J Med. 2015;373(14):1379–80.#SA1.
67. Strathdee SA, Beyrer C. Threading the needle—how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373(5):397–9. doi: 10.1056/NEJMp1507252 26106947
68. National Institutes of Health. Starting antiretroviral treatment early improves outcomes for HIV-infected individuals. Bethesda (Maryland): National Institutes of Health; 2015 May 27 [cited 2015 Jul 15]. https://www.nih.gov/news-events/news-releases/starting-antiretroviral-treatment-early-improves-outcomes-hiv-infected-individuals.
69. Pilcher C, Hatano HH, Dasgupta A, Jones D, Torres S, Calderon F, et al. Providing same day, observed ART to newly diagnosed HIV+ outpatients is associated with improved virologic suppression. Abstract WEAD0105LB. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention; 19–22 Jul 2015; Vancouver, Canada.
70. Schwarcz S, Hsu CL, Scheer S. Disparities and trends in viral suppression during a transition to a “Test and Treat” approach to the HIV epidemic, San Francisco, 2008–2012. J Acquir Immune Defic Syndr. 2015;70(5):529–37. doi: 10.1097/QAI.0000000000000794 26569177
71. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45(Suppl 4):S248–54.
72. Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc. 2012;15(1):10. doi: 10.1186/1758-2652-15-10 22360788
73. US Bureau of Labor Statistics. Consumer Price Index. Washington (District of Columbia): US Department of Labor; 2015 [cited 2015 March 31]. https://www.bls.gov/cpi/.
74. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007;5:11. doi: 10.1186/1478-7954-5-11 17967185
75. Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria. Pharmacoeconomics. 2011;29(1):51–62. doi: 10.2165/11584610-000000000-00000 21142278
76. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making. 1997;17(4):483–9. doi: 10.1177/0272989X9701700414 9343807
77. Walensky RP. Investing in people who inject drugs: a preponderance of opportunities. Ann Intern Med. 2016 Apr 26.
78. Boyd SJ, Fang LJ, Medoff DR, Dixon LB, Gorelick DA. Use of a ‘microecological technique’ to study crime incidents around methadone maintenance treatment centers. Addiction. 2012;107(9):1632–8. doi: 10.1111/j.1360-0443.2012.03872.x 22385066
79. Pollack HA, D’Aunno T. Dosage patterns in methadone treatment: results from a national survey, 1988–2005. Health Serv Res. 2008;43(6):2143–63. doi: 10.1111/j.1475-6773.2008.00870.x 18522665
80. Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making. 2011;31(4):675–92. doi: 10.1177/0272989X11409240 21653805
81. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd edition. Oxford: Oxford University Press; 2016.